The CDTI invests together with Ysios Capital and Asabys Partners in Anaconda Biomed, medical devices company neurovasculares

The CDTI Innovation, through its programme, together with Innvierte Ysios Capital and Asabys Partners, has reached an agreement with Anaconda Biomed to invest in the company.

Anaconda Biomed, based in spain, is in advanced stages clinics with your device ANA Funnel Catheter, a pioneering system designed to improve both efficiency as the safety of mechanical trombectomías in the treatment of acute ischaemic stroke, a major cause of death and disability in the world.

With a social and economic impact significantly, the stroke represents a critical challenge to the global level. According to recent data the stroke will affect the 25 per cent of adults aged 25 plus throughout their lives and represents an annual cost of more than eur 60 billion in europe. The innovation of Anaconda Biomed aligns itself with the public health goals, providing tools to address this issue.

ANA Funnel Catheter

ANA5 Advanced Neurovascular Access ™ (ANA Funnel Catheter) is a catheter designed to help neurovasculares procedures. The device consisting of a mesh of nitinol radiopaco in a sweep topped with a layer polimérica that allows for the arrest local flow. Currently, this catheter is a device under investigation and is not available for sale in the united states or in the european union.

Anaconda Biomed

Anaconda Biomed is an innovative company medical technology solutions to the latest generation trombectomía for the treatment of ischaemic stroke in the heart of its portfolio of products is ANA Funnel Catheter.

Anaconda Biomed has received funding of leading firms in life sciences, as Ysios Capital, Omega Funds, Innogest, Asabys Partners, Banco Sabadell and private investors. Moreover, through public subsidies, the company has been supported by INNVIERTE, INICIATIVA DE INVERSIÓN DE CDTI, E.P.E, Enisa, CDTI (Neotec), the ministry of science and innovation (programmes and Emplea Retos), the EIB EIT and Health.

Ysios Capital Partners

Ysios Capital is a spanish leading manager in venture capital which provides funding to enterprises of life sciences highly innovative treatments that are aimed at indications with a large medical need not covered. With offices in San Sebastian and Barcelona, is formed by a team of professionals diverse which aims to transform the capital in medical breakthroughs with a positive impact on society. Ysios Capital, founded in 2008, has more than eur 400 million in assets under management through its three funds.

Asabys Partners

Asabys Partners is a specialized risk capital in health, founded in 2018 by Josep Ll. Sanfeliu and Clara Campàs Alantra owned, with the support of the Banco Sabadell anchor. investor With around €300 million in assets under management and 18 owned Asabys invests in innovative companies disruptive and addressing unmet medical needs in the areas of biotechnology and pharmaceuticals and health technology investment in this company has been made since their vehicles Sabadell Asabys Health Innovation Investments SCR, SA, and Asabys Top Up Fund, RCF.

CDTI Innovation

The CDTI innovation is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology.

Additionally, through the initiative Innvierte Sustainable Economy, supports and facilitates the capitalization of technology companies. To date, the CDTI Innovation, through Innvierte, committed 1,795 M €in 42 investment vehicles that have invested in more than 271 companies, and through its joint investment line directly committed an amount of more than 522 M €in at least 160 companies.

More information:

Office of the press
prensa@cdti.es
91-581.55.00

On The Internet
Website:www.cdti.es
In Linkedin:https :// www.linkedin.com/company/29815
X:https :// twitter.com/CDTI _ innovation
On Youtube:https :// www.youtube.com/user/CDTIoficial

This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (@CDTI _ innovation).